

Public Declaration of Interests and Confidentiality Undertaking of European Medicines Agency (EMA)

SCIENTIFIC COMMITTEE MEMBERS AND EXPERTS

I, Aristotelis Bamias

Organisation/Company: N/A

Country: Greece

Declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

1.1 Employment

No interest declared

1.2 Consultancy

Time Period	Start Date	End Date	Name of pharmaceutical company	Type	Product name	Therapeutic indication	General role / Area of activity
Past	01-03-2014	01-11-2020	MSD	Cross product related/ general (non product related)	null	null	Chemotherapy_induced emesis
Past	01-11-2017	01-11-2020	IPSEN	Individual product related	Cabozantinib	Renal cancer	null
Past	01-10-2015	15-05-2023	Astra Zeneca	Individual product related	Durvalumab	Urothelial cancer	
Past	01-12-2016	01-06-2020	BMS	Individual product related	Nivolumab	Renal cancer, Urothelial cancer	null
Past	01-04-2016	01-04-2018	Pfizer	Cross product related/ general (non product related)	null	null	Treatment of renal cancer_ Axitinib

1.3 Strategic advisory role

Time Period	Start Date	End Date	Name of pharmaceutical company	Type	Product name	Therapeutic indication	General role / Area of activity
Past	01-09-2020	22-03-2023	GSK	Individual product related	ZeZula	Ovarian cancer	
Past	01-11-2016	01-06-2019	Novartis	Individual product related	Pazopanib	Renal cancer	null
Current	01-05-2016	22-03-2023	ROCHE	Individual product related	Atezolizumab	Urothelial cancer	null

1.4 Financial interests

Name of	Financial interest	Other comments

pharmaceutical company		
BMS	Compensation/Fees/Honoraria/etc.	Satellite lecture. Nivolumab
MSD	Compensation/Fees/Honoraria/etc.	Clinical Observation programme. Renal cancer
Astellas	Compensation/Fees/Honoraria/etc.	Satellite lecture. Enzalutamide
IPSEN	Compensation/Fees/Honoraria/etc.	Renal cancer. Cabozantinib

1.5 Principal investigator

No interest declared

1.6 Investigator

Time Period	Start Date	End Date	Name of pharmaceutical company	Product Name	Therapeutic indication
Past	01-04-2016	22-03-2023	Pfizer	Avelumab	Ovarian cancer
Past	01-02-2016	22-03-2023	Roche	Bevacizumab	Cervical cancer
Past	01-03-2018	22-03-2023	Roche	Atezolizumab	Ovarian cancer 1st_line
Current	10-05-2022		Roche	Atezolizumab	adjuvant
Current	01-09-2016	22-03-2023	Roche	Atezolizumab	Urothelial cancer 1st line
Past	01-06-2016	01-09-2019	Sanofi	Cabazitaxel	Prostate cancer
Past	01-04-2016	01-10-2019	Astra Zeneca	Durvalumab	Urothelial cancer_1st line
Past	01-02-2018	22-03-2023	Roche	Atezolizumab	Prostate Cancer
Past	01-10-2016	22-03-2023	BMS	Nivolumab	Urothelial cancer adjuvant
Current	01-05-2018	22-03-2023	Janssen_Cilag	Erdafitinib	Urothelial cancer relapsed
Past	01-12-2016	22-03-2023	Pfizer	Avelumab	Urothelial cancer maintenace
Past	01-05-2016	31-12-2022	Roche	Atezolizumab	Urothelial cancer_2nd line
Past	01-09-2017	22-03-2023	EISAI	Lenvatinib	Renal cancer
Current	01-03-2018	22-03-2023	BMS	Nivolumab	Urothelial cancer 1st_line

1.7 Grant / Funding to organisation /institution

Name of pharmaceutical company	Subject Matter
BMS	Urothelial radiotherapy
IPSEN	Renal cancer
Roche	Urothelial cancer

1.8 Close family member interest

No interest declared

1.9 Repurposing of a medicinal product

No interest declared

1.10 Any other interests or facts

Member of the Genitourinary Cancer Faculty of the European Society of Medical Oncology (ESMO) since 2012 Academic trials during the last 3 years 1. EFFICACY AND SAFETY OF BEVACIZUMAB/TEMESIROLIMUS COMBINATION AFTER FIRST_LINE anti_VEGF THERAPY IN ADVANCED RENAL CELL CARCINOMA EudraCT: 2010_020664_38 Sponsor: Hellenic Co_operative

Oncology Group (HeCOG) Funding by: Pfizer 2. A Retrospective Analysis of the Effectiveness of Everolimus as Second_line Treatment in Metastatic RCC after FailUre/IntolerancE of Pazopanib. The 'RESCUE' Study Sponsor: Hellenic Genito_Urinary Cancer Group (HGUCG) Funding by: Novartis 3. Patterns of praCtice and phaRmacoeconomic analysIS of the management of patIents with metaStatic renal cell carcinoma (mRCC) in Greece _the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG). Sponsor: Hellenic Genito_Urinary Cancer Group (HGUCG) Funding by: Novartis 4. A Phase 3 Randomized, Double_Blind, Placebo_Controlled, Multi_Center Study of AMG 386 With Paclitaxel and Carboplatin as First_line Treatment of Subjects With FIGO Stage III_IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers TRINOVA_3 Sponsor: Belgian Gynaecological Oncology Group (BGOG) Funding by: Amgen 5. Intravesical administration of Durvalumab (MEDI4736) to patients with high_risk, non_muscle_invasive bladder cancer (NMIBC). A phase II study with correlative biomarker studies Sponsor: Hellenic Genito_Urinary Cancer Group (HGUCG) Funding by: Astra Zeneca 6. OUTCOMES FROM TREATMENT OF METASTATIC RENAL_CELL CARCINOMA FOLLOWING FAILURE OF FIRST_LINE ANTI_VEGF/VEGFR THERAPY: REAL_LIFE EVIDENCE ON THE CHANGE OF THE TREATMENT PARADIGM_OVERCOME STUDY Sponsor: Hellenic Genito_Urinary Cancer Group (HGUCG) Funding by: Pfizer 7. Nivolumab plus chemoradiotherapy in patients with muscle_invasive bladder cancer (MIBC) not undergoing cystectomy: a phase II, randomized study. Sponsor: Hellenic Genito_Urinary Cancer Group (HGUCG) Funding by: BMS

1.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

2.1 Employment

No interest declared

2.2 Consultancy

No interest declared

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

No interest declared

2.5 Principal investigator

No interest declared

2.6 Investigator

No interest declared

2.7 Grant / Funding to organisation /institution

No interest declared

2.8 Close family member interest

No interest declared

2.9 Any other interests or facts

No interest declared

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.

- Not to disclose (or authorise any other person to disclose) in any way to any third party ¹ any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to indicate clearly that the views are my own if acting in my own capacity or those of the EMA, Management Board, Committee, Working Party, Expert Group or other group if acting on behalf of that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate and complete to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

1. Third party does not include employees of the National Competent Authorities who either have employment contracts that provide confidentiality obligations or are encompassed by confidentiality obligations under national legislation on professional secrecy.

Full Name: Aristotelis Bamias

Date: 2023-05-15

For definitions of activities etc, refer to the policy on handling of competing interests.